
News|Articles|March 1, 2011
FDA Pipeline Preview, March 2011 (Contrave, rabeprazole sodium extended-release capsules, Avodart, Mu Delta, Carfilzomib, Vascugel, INX-0818, vosaroxin, Acurox, fidaxomicin, melanoma cancer vaccine, NSI-566RSC, Regorafenib)
Recent FDA action (through, February 2011) related to Contrave, rabeprazole sodium extended-release capsules, Avodart, Mu Delta, Carfilzomib, Vascugel, INX-0818, vosaroxin, Acurox, fidaxomicin, melanoma cancer vaccine, NSI-566RSC, Regorafenib.
Advertisement
Complete response
Fast-track designation
Priority review
Orphan drug designations
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
HaVy Ngo-Hamilton, Pharm.D. | 2026 MHE Emerging Leaders in Healthcare
2
340B reform and drug shortages are among hospital pharmacy concerns, survey finds
3
Healthcare’s workforce has a scale problem, but new model is emerging
4
Dual-target ADC shows promising PFS signal in mCRPC | ASCO 2026
5

























